CN101683404B - Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof Download PDFInfo
- Publication number
- CN101683404B CN101683404B CN2008102116558A CN200810211655A CN101683404B CN 101683404 B CN101683404 B CN 101683404B CN 2008102116558 A CN2008102116558 A CN 2008102116558A CN 200810211655 A CN200810211655 A CN 200810211655A CN 101683404 B CN101683404 B CN 101683404B
- Authority
- CN
- China
- Prior art keywords
- weight portions
- chinese medicine
- medicine composition
- radix
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: coptis, red peony root, lotus plumule, rhubarb, spora lygodii and indigo naturalis. The traditional Chinese medicine composition has the functions of clearing away heat and toxic material and promoting diuresis and eliminating phlegm, and is clinically used for patients with acute hepatitis A and acute hepatitis B which belong to the dampness and heat in the liver and gallbladder and have the symptoms of distending pain in hypochondrium, dysphoria with smothery sensation, bitterness in the mouth, nausea, indigestion and loss of appetite, chest distress, abdominal distension, fatigue, hypodynamia, dark urine, and the like.
Description
Technical field
The invention provides a kind of Chinese medicine composition, particularly relate to a kind of Chinese medicine composition of treating syndrome of dampness-heat of liver and gallbladder.
Background technology
Acute viral hepatitis is mainly caused by the hepatitis virus A that has a liking for liver, B, C, D, E; Some non-special viruses of having a liking for liver also can start an inflammation of the liver like cytomegalovirus, Epstain-Barr virus, herpes simplex virus etc., but rare.The acute viral hepatitis that China takes place at present mainly is a hepatitis A; Viral hepatitis can be divided into the infectious hepatitis of intestinal biography property and the serum hepatitis of blood biography property, and the hepatitis pathological changes of intestinal biography property is from limitting the developed into chronic hepatitis of blood biography property.
The traditional Chinese medical science thinks that focusing on of acute hepatitis treatment is eliminating evil.Damp and hot and epidemic disease poison is morbific exopathogenic factor, and the imbalance of liver,spleen,kidney three dirty functions, or QI and blood deficiency is the main endogenous cause of ill of morbidity.The most true card of acute hepatitis though have visceral dysfunction and QI and blood to change, is characterized in: " the evil Sheng just do not declined ".Therefore, treatment focus on eliminating evil.Clinically, often can see general lassitude, weakly breathe hard, the resembling of weakness such as indigestion and loss of appetite, soreness of the waist and knees, yet this is due to the damp and hot heresy; Be " due to illness and empty ", healthy energy is not weak, can't see that virtual image is absurd throwing tonic; In order to avoid help the wet heat that helps; Cause the trouble of " close door and stay the bandit ", should be eliminating evil as treatment emphasis, " eliminating evil " promptly to set upright.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition of treating syndrome of dampness-heat of liver and gallbladder.
Another object of the present invention provides a kind of method for preparing of treating the Chinese medicine composition of syndrome of dampness-heat of liver and gallbladder.
The present invention also aims to provide the application of a kind of Chinese medicine composition in preparation treatment acute hepatitis A medicine.
The present invention also aims to provide the application of a kind of Chinese medicine composition in preparation treatment acute hepatitis B medicine.
The objective of the invention is to realize through following technical scheme:
The Chinese medicine composition of treatment syndrome of dampness-heat of liver and gallbladder of the present invention, process by following raw materials in weight portion medicine:
Rhizoma Coptidis 3-15 weight portion, Radix Paeoniae Rubra 10-25 weight portion, Plumula Nelumbinis 5-12 weight portion, Radix Et Rhizoma Rhei 2-15 weight portion, Spora Lygodii 10-40 weight portion, Indigo Naturalis 5-15 weight portion.
The preferred following raw materials in weight portion medicine of above-mentioned Chinese medicine composition is processed:
Rhizoma Coptidis 4-10 weight portion, Radix Paeoniae Rubra 15-20 weight portion, Plumula Nelumbinis 6-10 weight portion, Radix Et Rhizoma Rhei 6-10 weight portion, Spora Lygodii 10-20 weight portion, Indigo Naturalis 5-10 weight portion.
The method for preparing of above-mentioned Chinese medicine drug composition may further comprise the steps:
A, get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 10～16 times of water gagings and decoct each 1～3 hour 2～4 times; Filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃; 50～70 ℃ of vacuum dryings are ground into fine powder, and are subsequent use;
B, Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be subsequent use;
C, with step a gained dry extract fine powder and step b gained medical material fine powder, mix homogeneously is processed tablet, capsule, pill, granule, promptly gets.
Above-mentioned steps a is preferably coarse powder is added 12 times of water gagings decoctions 3 times, and each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings.
Rhizoma Coptidis heat clearing and damp drying in the pharmaceutical composition prescription of the present invention, eliminating fire and detoxication; The Radix Paeoniae Rubra clearing away heat and cooling blood, eliminating stasis to stop pain; The Plumula Nelumbinis clearing away heart-fire for tranquillization, restoring normal coordination between the heart and kidney, unsmoothing the sperm and stopping bleeding; The Radix Et Rhizoma Rhei purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation; The Spora Lygodii eliminating damp-heat, treating stranguria pain relieving; The Indigo Naturalis heat-clearing and toxic substances removing, removing heat from blood, arresting convulsion.Full side plays heat-clearing and toxic substances removing, the effect that dampness removing reduces phlegm altogether.Be used for acute first, the hepatitis B person that belongs to the syndrome of dampness-heat of liver and gallbladder, disease is seen association's rib distending pain, the dysphoria with smothery sensation bitter taste, and it is indigestion and loss of appetite to feel sick, and the vexed abdominal distention of wrist is refreshing tired weak, yellowish or reddish urine.
Following experimental example is used to further specify but is not limited to the present invention.
Experimental example 1 pharmacodynamics test
One, medicine of the present invention is to the protective effect of acute liver damage due to the thioacetamide
1 materials and methods
1.1 laboratory animal is selected 40 of SD rats for use, body weight 200-220g, male and female dual-purpose, cleaning level.
1.2 trial drug; Medicine of the present invention is according to the Chinese medicinal composition capsules agent of the present invention of embodiment 1 success preparation.The positive control medicine, commercially available liver heat removing toxic capsule is produced the accurate word Z20030010 of traditional Chinese medicines by Hangzhou miracle king pharmaceutcal corporation, Ltd.
1.3 main agents: thioacetamide, chemical reagents corporation provides by Beijing; The Fine Chemical Works production of cultivating people of ability of pentobarbital sodium, Tong County, Beijing; Tachypleus amebocyte lysate box, she changes clinical medicine scientific & technical corporation (Shanghai City medical science assay office) by Shanghai provides; ALT (ALT), asparagine acidic group conversion enzyme (AST) test kit are provided by Roche company; Tumor necrosis factor one Ot (TNF-n) radioimmunological kit is provided by the Beijing North biotechnology research.
1.4 key instrument: Reicheit-Jung2040 microtome: Germany; BH-2 optical microscope: 0lympus, Japan; Qwin image analysis system: Leica, Germany; The 752C ultraviolet-uisible spectrophotometer; Shanghai the 3rd analytical tool factory; GC-911 radioimmunity enumerator: University of Science and Technology of China,technology industry Corp; Hitachi's 7170 full-automatic biological analysers: Japan.
1.5 grouping and processing are divided into 4 groups at random with 40 rats: 10 of normal control groups, 10 of model group, 10 of drug group of the present invention, 10 of positive controls.Medicine of the present invention is irritated stomach according to the 0.27g/kg body weight, and 1 hour pneumoretroperitoneum injection thioacetamide (TAA) 600mg/kg body weight gives medicine of the present invention respectively at irritating stomach once more after 6 hours, 12 hours.The positive control medicine is irritated stomach according to the 0.27g/kg body weight, and 1 hour pneumoretroperitoneum injection thioacetamide (TAA) 600mg/kg body weight gives medicine of the present invention respectively at irritating stomach once more after 6 hours, 12 hours.Model group is irritated stomach and is given isometric distilled water, 1 hour pneumoretroperitoneum injection TAA, and dosage is the same, gives distilled water respectively at irritating stomach once more after 6 hours, 12 hours; The normal saline of normal control group lumbar injection equivalent.The normal saline of normal control group lumbar injection equivalent.Inject after 24 hours, with the pentobarbital sodium intraperitoneal injection of anesthesia of 45mg/kg body weight, in the aseptic blood of getting of ventral aorta, separation of serum, blood plasma are respectively applied for the mensuration of A, AST, TNF.oL and endotoxin content with each group rat.Get liver, use 10% formaldehyde fixed.
1.6 index determining is the PATHOMORPHOLOGICAL OBSERVATION OF PULLORUM of hepar damnification situation 1.: get liver, routine is drawn materials, FFPE, HE dyeing.Under the light microscopic it is carried out PATHOMORPHOLOGICAL OBSERVATION OF PULLORUM, and measure its damaged area percentage ratio with the Qwin image analysis system.Assay method: under 200 times of light microscopics, its damaged area percentage ratio is measured in 10 visuals field of picked at random, gets its meansigma methods.2. serum alt, AST active concentration determination carry out with Hitachi's 7170 automatic clinical chemistry analyzers.3. TNF.OL assay in the serum according to the appended description of test kit, carries out with GC-911 radioimmunity enumerator.3. endotoxin content is measured according to the appended description of test kit in the blood plasma, carries out with the 752C ultraviolet-uisible spectrophotometer.
2 results
2.1 morphological changes of various tissue components
1. normal control group: liver structure is normal, and tunicle does not thicken, and the lobule boundary is clear, and the liver plate is the center with the lobule central vein, is radial arrangement.The liver plate is a cell thickness.Sinus hepaticus is not seen expansion, does not also have narrow.The lobules of liver parenchyma is not seen degeneration and necrosis.The central vein wall does not have and thickens, and the portal area tee pipe is high-visible, and no lymphocytic infiltration is not seen connective tissue proliferation.Interstitial cell does not increase.
2. model group; Liver structure is normal basically, and tunicle does not thicken, and the lobules of liver boundary is still clear, and the liver plate is not seen and thickened.Visible multiple kitchen range shape blister degeneration of liver parenchyma and balloon appearance become, and visible fresh point-like, kitchen range shape, band shape and bridging necrosis.Necrosis region visible cell fragment, and see neutrophilic granulocyte, a small amount of eosinophilic granulocyte and lymphocytic infiltration.Visible regression of the inflammatory cell of infiltration and karyorrhexis.Visible circular eosinophilic body in the necrosis region.Point, the necrosis of kitchen range shape are more common in around the other sublobular vein of central vein, and serious place visible lobule center band is zonal necrosis, and necrosis region can link to each other with contiguous central zone or peripheral band sometimes, constitutes bridging necrosis.
3. drug group rat pathology finding of the present invention is similar with model group, but some kitchen range shape is downright bad, central zone is downright bad and bridging necrosis is light than model group all.
4. positive drug control rats pathology finding is similar with model group, but some kitchen range shape is downright bad, central zone is downright bad and bridging necrosis is light than model group all.
Further the graphical analysis result shows, the hepar damnification area of drug group rat of the present invention is starkly lower than model group.See table 1.
Table 1 is respectively organized the degree of impairment of rat liver
| Group | n | Hepar damnification area (%) |
| The normal control group | 10 | 0 |
| Model group | 10 | 14.99±2.73 |
| Drug group of the present invention | 10 | 9.55±2.13△△ |
| The positive drug matched group | 10 | 11.37±2.32△△ |
Compare △ △ P < 0.01 with model group
2.2 medicine of the present invention is seen table 2 to ALT, the active result of influence of AST in the hepatic injury rat blood serum.
Table 2 is respectively organized ALT in the rat blood serum, the active variation of AST (x ± s)
| Group | n | ALT(U/L) | AST(U/L) |
| The normal control group | 10 | 54.40±12.44 | 165.20±50.84 |
| Model group | 10 | 153.11±67.05** | 987.78±393.47** |
| Drug group of the present invention | 10 | 99.65±66.52 | 393.44±273.29*△△ |
| The positive drug matched group | 10 | 123.34±68.17 | 520.54±301.25*△△ |
Compare with the normal control group, * P 0.05, * * P < 0.01; Compare with model group, < 0.012.3 respectively organizes TNF-a in the rat serum to △ △ P, table 3 is seen in the endotoxin content variation.
Table 3 is respectively organized the variation (x ± s) of TNF-a in the rat serum, endotoxin content
| Group | n | TNF-a(fmol/ml) | Endotoxin (Ru/ml) |
| The normal control group | 10 | 3.39±9.974 | 0.16±0.06 |
| Model group | 10 | 5.90±0.69** | 1.59±0.22** |
| Drug group of the present invention | 10 | 4.36±0.78*△△ | 0.99±0.28**△△ |
| The positive drug matched group | 10 | 4.85±0.71*△△ | 1.21±0.24**△△ |
Compare * P < 0.05 with the normal control group.* P < 0.01; Compare △ △ P (0.01 with model group
Medicine of the present invention has the endogenous toxin of removing rope, reduces tumor necrosis factor content, protects hepatocellular remarkable effect, and its effect is superior to the positive control medicine.
The clinical efficacy of experimental example 2 treatment acute hepatitis As
1. object and method
The acute hepatitis A patient diagnosis meets " scheme of preventing and treating of viral hepatitis " standard of the 6th the national viral hepatitis meeting revision in nineteen ninety Shanghai 1.1 object is in hospital.Hepatitis A 16 examples, matched group 21 examples are planted to constitute etc. at age, sex and sick for two groups and are had comparability through the x2 check.
1.2 oral Chinese medicinal composition capsules agent of the present invention (0.5g/ grain) is organized in the method treatment, one time 2, three times on the one, 1 month was 1 course of treatment; The oral liver heat removing toxic capsule of matched group (the 0.5g/ grain is produced the accurate word Z20030010 of traditional Chinese medicines by Hangzhou miracle king pharmaceutcal corporation, Ltd), one time 2, three times on the one, 1 month was 1 course of treatment.
1.3 criterion of therapeutical effect is produce effects 1.: the course of treatment is when finishing; Clinical symptom disappearance or obviously improvement, hepatosplenomegaly bounces back to some extent, and ALT and Sb reduce to normal range. and 2. effective: clinical symptoms takes a turn for the better; The hepatosplenomegaly no change; ALT and Sb reduce more than 50% before the treatment. and 3. invalid: clinical symptoms does not have and is clearly better, and ALT and Sb level reduce less than 50% before the treatment, no change or increase the weight of to some extent. and total effective rate is that produce effects adds effectively.
2. result
Acute hepatitis A 16 examples, produce effects 10 examples (62.4%), effective 3 examples (18.8%), invalid 3 examples (18.8%), effective percentage 81.2%. acute hepatitis A 21 examples, produce effects 11 examples (52.4%), effective 3 examples (14.3%), invalid 7 examples (33.3%), effective percentage 66.7%.
Find out by above result of the test, acute hepatitis A Chinese medicine composition curative effect of the present invention all significantly is superior to the liver heat removing toxic capsule.
The clinical efficacy of experimental example 3 treatment acute hepatitis Bs
1. object and method
The object acute hepatitis B patient diagnosis of being in hospital meets " scheme of preventing and treating of viral hepatitis " standard of the national viral hepatitis meeting revision in nineteen ninety the 6th in Shanghai.Hepatitis B 30 examples, matched group 25 examples are planted to constitute etc. at age, sex and sick for two groups and are had comparability through the x2 check.
1.2 oral Chinese medicinal composition capsules agent of the present invention (0.5g/ grain) is organized in the method treatment, one time 2, three times on the one, 2 months was 1 course of treatment; The oral liver heat removing toxic capsule of matched group (the 0.5g/ grain is produced the accurate word Z20030010 of traditional Chinese medicines by Hangzhou miracle king pharmaceutcal corporation, Ltd), one time 2, three times on the one, 2 months was 1 course of treatment.
1.3 criterion of therapeutical effect is produce effects 1.: the course of treatment is when finishing; Clinical symptom disappearance or obviously improvement, hepatosplenomegaly bounces back to some extent, and ALT and Sb reduce to normal range. and 2. effective: clinical symptoms takes a turn for the better; The hepatosplenomegaly no change; ALT and Sb reduce more than 50% before the treatment. and 3. invalid: clinical symptoms does not have and is clearly better, and ALT and Sb level reduce less than 50% before the treatment, no change or increase the weight of to some extent. and total effective rate is that produce effects adds effectively.
2. result
Acute hepatitis B 30 examples, produce effects 16 examples (53.3%), effective 12 examples (40.0%), invalid 2 examples (6.7%), effective percentage is 93.3%; Matched group 25 examples; Produce effects 12 examples (48.0%); Effective 4 examples (16.0%), invalid 9 examples (36.0%), effective percentage is that 64.0%. hepatitis B patient has 12 routine HBeAg to be positive; Finishing cloudy commentaries on classics of back check 8 examples the course of treatment. matched group hepatitis B patient has 10 routine HBeAg positive, finishes cloudy commentaries on classics of check 2 examples the course of treatment. and there were significant differences for the negative conversion rate between two groups.
Find out by above result of the test, acute hepatitis B Chinese medicine composition curative effect of the present invention all significantly is superior to the liver heat removing toxic capsule.
The specific embodiment
Embodiment 1 capsule
Rhizoma Coptidis 100g, Radix Paeoniae Rubra 200g, Plumula Nelumbinis 80g, Radix Et Rhizoma Rhei 80g, Spora Lygodii 150g, Indigo Naturalis 60g.
Get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 12 times of water gagings and decoct three times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings are ground into fine powder, and are subsequent use; Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be subsequent use; With gained dry extract fine powder and medical material fine powder, mix homogeneously, filled capsules is processed 1000, promptly gets.
Embodiment 2 capsules
Rhizoma Coptidis 150g, Radix Paeoniae Rubra 150g, Plumula Nelumbinis 150g, Radix Et Rhizoma Rhei 150g, Spora Lygodii 150g, Indigo Naturalis 150g.
Get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 12 times of water gagings and decoct three times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings are ground into fine powder, and are subsequent use; Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be subsequent use; With gained dry extract fine powder and medical material fine powder, mix homogeneously, filled capsules is processed 1000, promptly gets.
Embodiment 3 capsules
Rhizoma Coptidis 200g, Radix Paeoniae Rubra 250g, Plumula Nelumbinis 50g, Radix Et Rhizoma Rhei 80g, Spora Lygodii 60g, Indigo Naturalis 50g.
Get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 12 times of water gagings and decoct three times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings are ground into fine powder, and are subsequent use; Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be subsequent use; With gained dry extract fine powder and medical material fine powder, mix homogeneously, filled capsules is processed 1000, promptly gets.
Embodiment 4 tablets
Rhizoma Coptidis 80g, Radix Paeoniae Rubra 180g, Plumula Nelumbinis 80g, Radix Et Rhizoma Rhei 70g, Spora Lygodii 180g, Indigo Naturalis 70g.
Get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 12 times of water gagings and decoct three times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings are ground into fine powder, and are subsequent use; Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be subsequent use; With gained dry extract fine powder and medical material fine powder, mix homogeneously, common process are processed 1000, promptly get.
Embodiment 5 granules
Rhizoma Coptidis 60g, Radix Paeoniae Rubra 180g, Plumula Nelumbinis 70g, Radix Et Rhizoma Rhei 70g, Spora Lygodii 130g, Indigo Naturalis 80g.
Get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 12 times of water gagings and decoct three times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings are ground into fine powder, and are subsequent use; Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be subsequent use; With gained dry extract fine powder and medical material fine powder, mix homogeneously, common process is processed granule.
Embodiment 6 embodiment 1-5 are to ALT, the active influence of AST in the hepatic injury rat blood serum
1, material method
Identical with experimental example 1 pharmacodynamics test method.
2, result
Table four is respectively organized ALT in the rat blood serum, the active variation of AST (x ± s)
| Group | n | ALT(U/L) | AST(U/L) |
| The normal control group | 10 | 52.50±10.24 | 158.35±50.46 |
| Model group | 10 | 149.08±68.42** | 979.87±390.25** |
| Embodiment 1 capsule | 10 | 98.76±65.38 | 391.15±272.40*△△ |
| Embodiment 2 capsules | 10 | 130.52±67.50 | 490.70±279.65*△△ |
| Embodiment 3 capsules | 10 | 128.52±67.50 | 516.70±299.68*△△ |
| Embodiment 4 tablets | 10 | 110.23±55.50 | 415.15±189.40 |
| Embodiment 5 granules | 10 | 120.34±57.50 | 430.56±230.40 |
Compare with the normal control group, * P 0.05, * * P < 0.01; Compare △ △ P < 0.01 with model group
Claims (6)
1. Chinese medicine composition that is used to treat syndrome of dampness-heat of liver and gallbladder is characterized in that this Chinese medicine composition processed by following raw materials in weight portion medicine:
Rhizoma Coptidis 4-10 weight portion, Radix Paeoniae Rubra 15-20 weight portion, Plumula Nelumbinis 6-10 weight portion, Radix Et Rhizoma Rhei 6-10 weight portion, Spora Lygodii 10-20 weight portion, Indigo Naturalis 5-10 weight portion.
2. Chinese medicine composition according to claim 1 is characterized in that this Chinese medicine composition processed by following raw materials in weight portion medicine:
Rhizoma Coptidis 10 weight portions, Radix Paeoniae Rubra 20 weight portions, Plumula Nelumbinis 8 weight portions, Radix Et Rhizoma Rhei 8 weight portions, Spora Lygodii 15 weight portions, Indigo Naturalis 6 weight portions.
3. Chinese medicine composition according to claim 1 is characterized in that this Chinese medicine composition processed by following raw materials in weight portion medicine:
Rhizoma Coptidis 8 weight portions, Radix Paeoniae Rubra 18 weight portions, Plumula Nelumbinis 8 weight portions, Radix Et Rhizoma Rhei 7 weight portions, Spora Lygodii 18 weight portions, Indigo Naturalis 7 weight portions.
4. Chinese medicine composition according to claim 1 is characterized in that this Chinese medicine composition processed by following raw materials in weight portion medicine:
Rhizoma Coptidis 6 weight portions, Radix Paeoniae Rubra 18 weight portions, Plumula Nelumbinis 7 weight portions, Radix Et Rhizoma Rhei 7 weight portions, Spora Lygodii 13 weight portions, Indigo Naturalis 8 weight portions.
5. like the method for preparing of said any one Chinese medicine composition of claim 1-4, it is characterized in that this may further comprise the steps:
A, get Rhizoma Coptidis, Radix Paeoniae Rubra, Plumula Nelumbinis mixed powder and be broken into coarse powder, add 10～16 times of water gagings and decoct each 1～3 hour 2～4 times; Filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃; 50～70 ℃ of vacuum dryings are ground into fine powder, and are subsequent use;
B, Radix Et Rhizoma Rhei, Indigo Naturalis, Spora Lygodii pulverizing medicinal materials are crossed 80 mesh sieves, and be subsequent use;
C, with step a gained dry extract fine powder and step b gained medical material fine powder, mix homogeneously is processed tablet, capsule, pill, granule, promptly gets.
6. like the said method for preparing of claim 5, it is characterized in that among the step a coarse powder being added 12 times of water gagings decocts 3 times, each 1 hour, filter, collecting decoction, relative density is 1.08～1.14 extractum when being concentrated into 50 ℃, 60 ℃ of vacuum dryings.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102116558A CN101683404B (en) | 2008-09-22 | 2008-09-22 | Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102116558A CN101683404B (en) | 2008-09-22 | 2008-09-22 | Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101683404A CN101683404A (en) | 2010-03-31 |
| CN101683404B true CN101683404B (en) | 2012-06-13 |
Family
ID=42046934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102116558A Active CN101683404B (en) | 2008-09-22 | 2008-09-22 | Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101683404B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325709A (en) * | 2000-05-25 | 2001-12-12 | 黄亚平 | Capsule for removing heat from liver and detoxicating and its preparing process |
-
2008
- 2008-09-22 CN CN2008102116558A patent/CN101683404B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325709A (en) * | 2000-05-25 | 2001-12-12 | 黄亚平 | Capsule for removing heat from liver and detoxicating and its preparing process |
Non-Patent Citations (1)
| Title |
|---|
| 殷晓轩.肝病临床处方配伍方法探讨.《山西中医》.2005,第21卷(第4期),第5-7页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101683404A (en) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101332284B (en) | Chinese traditional medicine composition for treating ulcerative colitis and its preparation method | |
| WO2022036779A1 (en) | Huashibaidu granule, preparation method therefor and anti-viral drug | |
| CN101264217A (en) | Chinese medicine assembly for nourishing yin and tonifying kidney, promoting qi and promoting blood circulation, and relaxing tendons and collaterals | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN111729054A (en) | Dampness-resolving toxin-vanquishing traditional Chinese medicine composition, traditional Chinese medicine preparation, preparation method and application thereof | |
| CN108714205B (en) | Traditional Chinese medicine granule for treating spleen-kidney yang deficiency type IgA nephropathy and preparation method and application thereof | |
| CN108379365B (en) | Medicine for preventing and treating diarrhea-predominant irritable bowel syndrome and preparation method and application thereof | |
| CN101683404B (en) | Traditional Chinese medicine composition for treating dampness and heat in liver and gallbladder and preparation method thereof | |
| CN115634275A (en) | Traditional Chinese medicine preparation for treating liver cancer liver stagnation and spleen deficiency stasis toxin syndrome | |
| CN101850063A (en) | Medicinal preparation for preventing and treating gout and preparation method | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN111920849B (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation containing same | |
| CN114558094A (en) | Sanqi dampness eliminating formula and application thereof | |
| CN101618085B (en) | Traditional Chinese medicine composition for treating liver and gallbladder dampness-heat disease and preparation method thereof | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN102652819A (en) | Fuyankang dispersible tablet and preparation method thereof | |
| CN100398097C (en) | Siji sanhuang new preparation and preparing method and application | |
| CN116019882B (en) | Medicine for preventing and/or treating silicosis and application thereof | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN109700972A (en) | Chinese medicine composition, preparation method and application | |
| WO2014032541A1 (en) | Chinese medicinal preparation for treating aids and preparation method thereof | |
| TWI844079B (en) | Chinese medicine composition and its preparation method and application | |
| CN112569313B (en) | Traditional Chinese medicine composition for treating nephropathy | |
| CN102406869B (en) | Intestine-protecting and detoxifying micro pellets and use thereof | |
| WO2023025228A1 (en) | Traditional chinese medicine composition, and preparation method therefor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |